QNTA News:
Medolife Rx Completes Initial Meeting With Bioethics Committee, Preparing For Commencement Of Phase II Clinical Trial On Lead Drug Candidate
via NewMediaWire - Medolife Rx, Inc. ("Medolife"), a global integrated bioceutical company with R&D, manufacturing, and consumer product distribution, which is a majority owned subsidiary of Quanta, Inc. (OTCPINK:QNTA), announced today that it completed its initial meetings with CONABIOS, the medical ethics committee that oversees all clinical trial programs in the Dominican Republic (DR).
The meeting outlined the next steps in its clinical program on Escozine(R) as a treatment for the SARS-CoV-2 (COVID-19) virus and the Company is seeking approval to commence clinical trials.
The Company has completed significant preclinical safety and efficacy trials in the DR, which included more than 500 participants.
The results of those studies demonstrated the efficacious nature of Escozine(R) in fighting viral infections, specifically in COVID-19 patients, where data showed a reduction in severity and duration of symptoms as well as a decrease in the length of positive tests. Additionally, throughout the preclinical trials, no patients experienced adverse effects to the drug candidate at any dosing level, establishing that the drug is safe and non-toxic.
This data was submitted to the Ministry of Health, which led to not only the re-registration of Escozine(R) as a natural alternative medicine in cancer treatment, but enabled the Company to seek medical ethics committee approval to begin Phase II human trials on Escozine(R) as a COVID-19 therapeutic.
News 
Market Data 
Discover 
